Tag: Warning Letter

CHC_DTCadvertisement2

01/17/2022

OPDP, Lilly Come to Terms Over TV Ads for Migraine Drug

CHC_DTCadvertisement2

03/15/2021

Two Recent OPDP Letters Prompted by “Bad Ad Program” Complaints

FDA-News (1)

10/12/2020

Bad Ad Complaints Yield Two OPDP Warning Letters, One on COVID Email Claims

FDA-News (1)

05/26/2020

By One Measure, 2020 OPDP Enforcement Is Off to Slow Start

thermometer-temperature-fever-flu

05/04/2020

As COVID-19 Pandemic Continues, Promotion of Unapproved “Cures” Abounds

CHC_FDA-Regulatory Images1

04/13/2020

FDA Streamlines COVID-19 Product Pathways, Continues to Crack Down on Misleading Claims

CHC_FDA-Regulatory Images1

03/16/2020

FDA and FTC: Coronavirus Products Are Fraudulent, Could Delay Treatment

CHC_FDA-Regulatory Images1

12/20/2019

Press Release Highlighting Omission of Risk Warning Letter Closes OPDP’s Enforcement Year

CHC_FDA-Regulatory Images1

10/07/2019

OPDP Cites Risk Presentation Issues in YouTube Video, Email in New Enforcement Letters